|
|
|
| Short and Long Term Effects of Transcatheter Arterial Chemoembolization Combined with Portal Vein 125 Iodine Seed Implantation in the Treatment of Liver Cancer Complicated with Portal Vein Tumor Thrombus |
| ZHAO Yong-hua, BAI Xue-mei, LIU Ya-min, et al |
| Department of interventional vascular, Chang'an District Hospital, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710100, Shaanxi |
|
|
|
|
Abstract 【Objective】To investigate the short-term and long-term effect and safety of transcatheter arterial chemoembolization (TACE) combined with portal vein 125 iodine (125I) seed implantation in the treatment of liver cancer complicated with portal vein tumor thrombus (PVTT). 【Methods】 A total of 90 patients with liver cancer complicated with PVTT was randomly divided into control group and observation group. The control group was treated with TACE, and the observation group was treated with TACE combined with portal vein 125I seed implantation. The serological indexes, recurrence rate, survival rate, progression free survival time (PFS) and overall survival time (OS) were compared between the two groups before and after treatment. The short-term efficacy of primary liver tumor and PVTT and the incidence of adverse reactions during treatment were compared between the two groups. 【Results】(1) the remission rate of primary tumor and PVTT in the observation group were significantly higher than those in the control group (P<0.05). (2) After treatment, the serum levels of alpha fetoprotein (AFP) and carcinoembryonic antigen (CEA) in the observation group were lower than those in the control group, and the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL) in the observation group were higher than those in the control group (P<0.05). (3) The 1-year recurrence rate in the observation group was lower than that in the control group (22.2% vs 28.9%, P<0.05), and the 1, 2 and 3-year cumulative survival rates were higher than those in the control group (73.3% vs 57.8%, 44.4% vs 24.4%, 33.3% vs 15.6%, respectively) (P<0.05). The average PFS and OS in the observation group were longer than those in the control group (all P<0.05). (4) There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). 【Conclusion 】 TACE combined with 125I seed implantation in portal vein is effective in the treatment of liver cancer complicated with PVTT. It can effectively control the progression of primary tumor and PVTT, prolong the survival time and improve the survival rate, and has good safety.
|
|
Received: 15 July 2019
|
|
|
|
|
|
[1] 罗君,郑家平,邵国良,等.肝动脉化学治疗栓塞联合125I粒子植入和索拉非尼治疗肝细胞癌门静脉癌栓的疗效比较[J].中华肝脏病杂志,2018,26(4):298-304.
[2] WOO H Y, HEO J. New perspectives on the management of hepatocellular carcinoma with portal vein tumor thrombosis [J].Clin Mol Hepatol,2015, 21(1): 115-121.
[3] 周熠,苏洪英,洪铎,等.碘125粒子植入联合TACE治疗原发性肝癌合并门静脉癌栓疗效及生存分析[J].中华肿瘤防治杂志,2018,25(23):1664-1669.
[4] 黄宁,杨维竹,江娜,等.TACE 联合经皮125I粒子植入序贯治疗肝癌伴门静脉主干癌栓临床研究[J].临床放射学杂志,2014,33(11):1416-1420.
[5] LENCIONI R.Modified RECIST (mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010, 30(1): 52-60.
[6] JEONG S W.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J].Gut Liver,2013,7(10): 696-703.
[7] KATAGIRI S, YAMAMOTO M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J].Surg Today,2014,44(2):219- 226.
[8] 黄文薮.TACE 联合125I放射性粒子植入治疗肝细胞癌门静脉癌栓[J].介入放射学杂志,2015,24(6):488-493.
[9] 蒋丽,韩东明,胡鸿涛,等.125I粒子植入联合肝动脉化疗栓塞术预防原发性肝癌合并门静脉癌栓消化道出血[J].中华放射学杂志,2016,50(8):784-788.
[10] 王巧瑜,潘洁,周元敏.经肝动脉化疗栓塞术联合门静脉内125I粒子植入治疗原发性肝癌合并门静脉癌栓的效果观察[J].临床肝胆病杂志,34(1):137-141. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1419-1421. |
|
|
|
|
2021, Vol. 38 
